ClinicalTrials.gg
RecruitingNCT07849231CLARITY-101Updated Oct 27, 2026

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

A Phase 1 interventional study of DMR-001 and Ruxolitinib in Myeloproliferative Neoplasms (MPNs), sponsored by Damora Therapeutics. Recruiting at 36 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Damora Therapeutics · Phase 1, Interventional, and Treatment

How we know

Updated Oct 27, 2026First site in United StatesSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 484 studies in Myeloproliferative Disorders with a site in United States — 58 open to participants now, 92 under way, 8 of them phase 3. Myeloproliferative Disorders · United States.

Planned enrollment
36th of 378
250 · median 40
Started
2026
with 11 others
Phase 1
107 of 484
17 open now
Primary completion
2030-06
later than 80 of 90 live
Registered
484th of 484
by date

Among the 484 studies in Myeloproliferative Disorders with a site in United States, this one is the 36th largest by planned enrollment of the 378 interventional ones that give a count, is one of 12 that started in 2026, is one of 107 in phase 1, reaches primary completion later than 80 of the 90 other live ones, and was the 484th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

58 of the 484 studies in Myeloproliferative Disorders with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 484 studies in Myeloproliferative Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.

03

Conditions studied

  • Myeloproliferative Neoplasms (MPNs)

Keywords

  • Myeloproliferative Neoplasms
  • Myelofibrosis
  • Essential Thrombocythemia
  • CALR mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed , which includes compliance with the requirements and restrictions listed in the ICF and the protocol.
  • Diagnosis/confirmation of ET or MF as defined in the protocol.
  • Documented CALR exon-9 mutation.
  • Willingness to undergo bone marrow and aspiration per the Schedule of Assessments.

Exclusion criteria

Exclusion Criteria:

  • Presence of any unless participant has been disease free for at least 2 years.
  • History of major bleeding or thrombosis within the last 3 months prior to study enrollment.
  • Prior hematopoietic stem cell transplantation or donor leukocyte infusion, or such transplantation or infusion is planned.
  • Participants with laboratory values exceeding protocol defined thresholds.
  • History of or uncontrolled cardiac disease.
  • Active , or .
  • Known to DMR-001 or ruxolitinib or any of their components.

Other protocol defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Part 1: DMR-001 monotherapy dose escalation phase.

    DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the protocol defined starting dose and dosing schedule to identify the maximum tolerated dose and/or recommended dose(s) for expansion.

    Drug: DMR-001

  • Experimental
    Part 2: DMR-001 monotherapy dose expansion phase.

    DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined recommended dose(s) for expansion based on Part 1.

    Drug: DMR-001

  • Experimental
    Part 3: DMR-001 and ruxolitinib combination dose escalation followed by dose expansion.

    DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined dose and regimen, but in combination with an oral tablet of ruxolitinib, a standard of care drug approved therapy for the treatment of MF.

    Drug: DMR-001 · Drug: Ruxolitinib

Interventions

  • DrugDMR-001

    DMR-001 will be administered at protocol defined dose at a frequency of every 4 weeks.

  • Ruxolitinib will be administered according to Prescribing Information/SmPC.

    Also known as: Jakafi, Jakavi

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of DMR-001 & determine the MTD, RDE(s), and/or recommended Phase 2 dose(s) in participants with CALR-mutant MPNs, when administered as monotherapy or in combination with ruxolitinib

    Incidence and severity of AEs and SAEs, including DLTs and AEs resulting in dose modification (interruption, reduction, or discontinuation)

    Time frame: Up to 672 days

Secondary outcomes

  1. Evaluate preliminary clinical activity of DMR-001 as a monotherapy in participants with CALR-mutant ET

    Objective response rate based on MPN specific response criteria

    Time frame: Up to 672 days

  2. Evaluate preliminary clinical activity of DMR-001 as a monotherapy or in combination with ruxolitinib in participants with CALR-mutant MF

    Established by looking at overall response rate based on MPN specific response criteria, protocol defined spleen volume reduction and protocol defined anemia response.

    Time frame: Up to 672 days

  3. Pharmacokinetics parameter: Cmax of DMR-001 when administered as monotherapy or in combination with ruxolitinib

    Maximum observed plasma concentration of DMR-001 monotherapy or DMR-001 in combination with ruxolitinib

    Time frame: Up to 672 days

  4. Pharmacokinetics parameter: Tmax of DMR-001 when administered as monotherapy or in combination with ruxolitinib

    Time to reach the maximum concentration of DMR-001 monotherapy or DMR-001 in combination with ruxolitinib

    Time frame: Up to 672 days

  5. Pharmacokinetics parameter: AUC(0-t) of DMR-001 when administered as monotherapy or in combination with ruxolitinib

    Area under the concentration-time curve up to the last measurable concentration of DMR-001 monotherapy or DMR-001 in combination with ruxolitinib

    Time frame: Up to 672 days

  6. Pharmacokinetics parameter: t1/2 of DMR-001 when administered as monotherapy or in combination with ruxolitinib

    Apparent terminal phase disposition half-life of DMR-001 monotherapy or DMR-001 in combination with ruxolitinib

    Time frame: Up to 672 days

  7. Assess the immunogenicity of DMR-001

    Incidence and persistence of anti-drug antibodies and neutralizing antibodies

    Time frame: Up to 672 days

07

Study locations

3 of 36 sites recruiting
  • Site US07
    Birmingham, Alabama 35233, United States
    Not yet recruiting
  • Site US26
    Gilbert, Arizona 85234, United States
    Not yet recruiting
  • Site US11
    Duarte, California 91010, United States
    Not yet recruiting
  • Site US25
    Irvine, California 92618, United States
    Not yet recruiting
  • Site US04
    Tampa, Florida 33612, United States
    Not yet recruiting
  • Site US15
    Atlanta, Georgia 30307, United States
    Not yet recruiting
  • Site US21
    Kansas City, Kansas 66160, United States
    Not yet recruiting
  • Site US18
    Baltimore, Maryland 21287, United States
    Not yet recruiting
  • Site US03
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Site US12
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Site US06
    Ann Arbor, Michigan 48109, United States
    Not yet recruiting
  • Site US08
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Site US17
    Babylon, New York 11702, United States
    Not yet recruiting
  • Site US01
    New York, New York 10029, United States
    Not yet recruiting
  • Site US02
    New York, New York 10065, United States
    Not yet recruiting
  • Site US14
    Charlotte, North Carolina 28204, United States
    Not yet recruiting
  • Site US24
    Durham, North Carolina 27705, United States
    Not yet recruiting
  • Site US13
    Winston-Salem, North Carolina 27103, United States
    Not yet recruiting
  • Site US05
    Columbus, Ohio 43210, United States
    Not yet recruiting
  • Site US20
    Eugene, Oregon 97401, United States
    Not yet recruiting
  • Site US19
    Nashville, Tennessee 37203, United States
    Not yet recruiting
  • Site US10
    Houston, Texas 77030, United States
    Not yet recruiting
  • Site US16
    Salt Lake City, Utah 84106, United States
    Not yet recruiting
  • Site US23
    Richmond, Virginia 23219, United States
    Not yet recruiting
  • Site US22
    Seattle, Washington 98109, United States
    Not yet recruiting
  • Site AU08
    Liverpool, New South Wales 2170, Australia
    Not yet recruiting
  • Site AU07
    Newcastle, New South Wales 2298, Australia
    Not yet recruiting
  • Site AU06
    Sydney, New South Wales 2031, Australia
    Not yet recruiting
  • Site AU09
    Sydney, New South Wales 2050, Australia
    Recruiting
  • Site AU11
    Brisbane, Queensland 4006, Australia
    Not yet recruiting
  • Site AU10
    Sunshine Coast, Queensland 4575, Australia
    Not yet recruiting
  • Site AU01
    Adelaide, South Australia 5042, Australia
    Not yet recruiting
  • Site AU02
    Melbourne, Victoria 3002, Australia
    Recruiting
  • Site AU03
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Site AU04
    Melbourne, Victoria 3168, Australia
    Not yet recruiting
  • Site AU05
    Perth, Western Australia 6150, Australia
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2030, 45 months later.

Of 40 phase 1 interventional studies under Myeloproliferative Disorders, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 140. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
33 sites added, 1 site removed — first site in United States. Site AU03 is now Recruiting
Show 33 added (25 United States, 8 Australia)
  • Site US07 · Birmingham, United States
  • Site US26 · Gilbert, United States
  • Site US11 · Duarte, United States
  • Site US25 · Irvine, United States
  • Site US04 · Tampa, United States
  • Site US15 · Atlanta, United States
  • Site US21 · Kansas City, United States
  • Site US18 · Baltimore, United States
  • Site US03 · Boston, United States
  • Site US12 · Boston, United States
  • Site US06 · Ann Arbor, United States
  • Site US08 · St Louis, United States
  • Site US17 · Babylon, United States
  • Site US01 · New York, United States
  • Site US02 · New York, United States
  • Site US14 · Charlotte, United States
  • Site US24 · Durham, United States
  • Site US13 · Winston-Salem, United States
  • Site US05 · Columbus, United States
  • Site US20 · Eugene, United States
  • Site US19 · Nashville, United States
  • Site US10 · Houston, United States
  • Site US16 · Salt Lake City, United States
  • Site US23 · Richmond, United States
  • Site US22 · Seattle, United States
  • Site AU07 · Newcastle, Australia
  • Site AU06 · Sydney, Australia
  • Site AU11 · Brisbane, Australia
  • Site AU10 · Sunshine Coast, Australia
  • Site AU01 · Adelaide, Australia
  • …and 3 more on the registry record
Show 1 removed
  • Site AU06 · Melbourne, Australia
Oct 27, 2026
Title
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms→A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Oct 7, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 3 updates
  1. Oct 27, 2026
    33 sites added, 1 site removed — first site in United States. Site AU03 is now Recruiting
    Show 33 added (25 United States, 8 Australia)
    • Site US07 · Birmingham, United States
    • Site US26 · Gilbert, United States
    • Site US11 · Duarte, United States
    • Site US25 · Irvine, United States
    • Site US04 · Tampa, United States
    • Site US15 · Atlanta, United States
    • Site US21 · Kansas City, United States
    • Site US18 · Baltimore, United States
    • Site US03 · Boston, United States
    • Site US12 · Boston, United States
    • Site US06 · Ann Arbor, United States
    • Site US08 · St Louis, United States
    • Site US17 · Babylon, United States
    • Site US01 · New York, United States
    • Site US02 · New York, United States
    • Site US14 · Charlotte, United States
    • Site US24 · Durham, United States
    • Site US13 · Winston-Salem, United States
    • Site US05 · Columbus, United States
    • Site US20 · Eugene, United States
    • Site US19 · Nashville, United States
    • Site US10 · Houston, United States
    • Site US16 · Salt Lake City, United States
    • Site US23 · Richmond, United States
    • Site US22 · Seattle, United States
    • Site AU07 · Newcastle, Australia
    • Site AU06 · Sydney, Australia
    • Site AU11 · Brisbane, Australia
    • Site AU10 · Sunshine Coast, Australia
    • Site AU01 · Adelaide, Australia
    • …and 3 more on the registry record
    Show 1 removed
    • Site AU06 · Melbourne, Australia
  2. Oct 7, 2026
    Title Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms→A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
    + 1 other change: verification date
  3. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849231
Lead sponsor
Damora Therapeutics
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Damora Therapeutics Medical Monitor
Contact
ClinicalTrials@Damoratx.com
+1 782-281-9020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion